Sylvant Injection, Powder, For Solution
NDC 73090-421
Product Information
Sylvant (siltuximab) is a BLA-approved product labeled by Recordati Rare Diseases, Inc.. Siltuximab is used to treat a certain rare illness (multicentric Castleman's disease - MCD) if you do not have HIV or herpes infections. It is supplied as a injection, powder, for solution for intravenous administration. This product entry covers the primary NDC 73090-421 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 73090-421?
What are the uses of this product?
What are Active Ingredients of this product?
- SILTUXIMAB 400 mg/1 - a chimeric anti-interleukin-6 antibody for treatment of multiple myeloma and renal cell carcinoma
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- SILTUXIMAB (UNII: T4H8FMA7IM)
- SILTUXIMAB (UNII: T4H8FMA7IM) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SUCROSE (UNII: C151H8M554)
- HISTIDINE (UNII: 4QD397987E)
- POLYSORBATE 80 (UNII: 6OZP39ZG8H)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1658132 - siltuximab 100 MG Injection
- RxCUI: 1658135 - Sylvant 100 MG Injection
- RxCUI: 1658135 - siltuximab 100 MG Injection [Sylvant]
- RxCUI: 1658139 - siltuximab 400 MG Injection
- RxCUI: 1658141 - Sylvant 400 MG Injection
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.
Patient Education
Siltuximab Injection
Siltuximab injection is used to treat multicentric Castleman's disease (MCD; abnormal overgrowth of lymph cells in more than one part of the body that may cause symptoms and may increase the risk of developing a serious infection or cancer) in people who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection. Siltuximab is in a class of medications called monoclonal antibodies. It works by blocking the action of a natural substance that causes increased growth of lymph cells in people with MCD.
[Learn More]
* Please review the full disclaimer at the bottom of this page.